Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Susceptibility to hormone-mediated cancer is reflected by different tick rates of the epithelial and general epigenetic clock

JE. Barrett, C. Herzog, YN. Kim, TE. Bartlett, A. Jones, I. Evans, D. Cibula, M. Zikan, L. Bjørge, N. Harbeck, N. Colombo, SJ. Howell, AF. Rådestad, K. Gemzell-Danielsson, M. Widschwendter

. 2022 ; 23 (1) : 52. [pub] 20220222

Language English Country Great Britain

Document type Journal Article, Research Support, Non-U.S. Gov't

Persistent link   https://www.medvik.cz/link/bmc22019369

Grant support
Department of Health - United Kingdom

BACKGROUND: A variety of epigenetic clocks utilizing DNA methylation changes have been developed; these clocks are either tissue-independent or designed to predict chronological age based on blood or saliva samples. Whether discordant tick rates between tissue-specific and general epigenetic clocks play a role in health and disease has not yet been explored. RESULTS: Here we analyze 1941 cervical cytology samples, which contain a mixture of hormone-sensitive cervical epithelial cells and immune cells, and develop the WID general clock (Women's IDentification of risk), an epigenetic clock that is shared by epithelial and immune cells and optimized for cervical samples. We then develop the WID epithelial clock and WID immune clock, which define epithelial- and immune-specific clocks, respectively. We find that the WID-relative-epithelial-age (WID-REA), defined as the difference between the epithelial and general clocks, is significantly reduced in cervical samples from pre-menopausal women with breast cancer (OR 2.7, 95% CI 1.28-5.72). We find the same effect in normal breast tissue samples from pre-menopausal women at high risk of breast cancer and show that potential risk reducing anti-progesterone drugs can reverse this. In post-menopausal women, this directionality is reversed. Hormone replacement therapy consistently leads to a significantly lower WID-REA in cancer-free women, but not in post-menopausal women with breast or ovarian cancer. CONCLUSIONS: Our findings imply that there are multiple epigenetic clocks, many of which are tissue-specific, and that the differential tick rate between these clocks may be an informative surrogate measure of disease risk.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22019369
003      
CZ-PrNML
005      
20220804135611.0
007      
ta
008      
220720s2022 xxk f 000 0|eng||
009      
AR
024    7_
$a 10.1186/s13059-022-02603-3 $2 doi
035    __
$a (PubMed)35189945
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxk
100    1_
$a Barrett, James E $u European Translational Oncology Prevention and Screening (EUTOPS) Institute, Milser Str. 10, 6060, Hall in Tirol, Austria $u Research Institute for Biomedical Aging Research, Universität Innsbruck, 6020, Innsbruck, Austria
245    10
$a Susceptibility to hormone-mediated cancer is reflected by different tick rates of the epithelial and general epigenetic clock / $c JE. Barrett, C. Herzog, YN. Kim, TE. Bartlett, A. Jones, I. Evans, D. Cibula, M. Zikan, L. Bjørge, N. Harbeck, N. Colombo, SJ. Howell, AF. Rådestad, K. Gemzell-Danielsson, M. Widschwendter
520    9_
$a BACKGROUND: A variety of epigenetic clocks utilizing DNA methylation changes have been developed; these clocks are either tissue-independent or designed to predict chronological age based on blood or saliva samples. Whether discordant tick rates between tissue-specific and general epigenetic clocks play a role in health and disease has not yet been explored. RESULTS: Here we analyze 1941 cervical cytology samples, which contain a mixture of hormone-sensitive cervical epithelial cells and immune cells, and develop the WID general clock (Women's IDentification of risk), an epigenetic clock that is shared by epithelial and immune cells and optimized for cervical samples. We then develop the WID epithelial clock and WID immune clock, which define epithelial- and immune-specific clocks, respectively. We find that the WID-relative-epithelial-age (WID-REA), defined as the difference between the epithelial and general clocks, is significantly reduced in cervical samples from pre-menopausal women with breast cancer (OR 2.7, 95% CI 1.28-5.72). We find the same effect in normal breast tissue samples from pre-menopausal women at high risk of breast cancer and show that potential risk reducing anti-progesterone drugs can reverse this. In post-menopausal women, this directionality is reversed. Hormone replacement therapy consistently leads to a significantly lower WID-REA in cancer-free women, but not in post-menopausal women with breast or ovarian cancer. CONCLUSIONS: Our findings imply that there are multiple epigenetic clocks, many of which are tissue-specific, and that the differential tick rate between these clocks may be an informative surrogate measure of disease risk.
650    _2
$a stárnutí $x genetika $7 D000375
650    _2
$a zvířata $7 D000818
650    12
$a nádory prsu $x genetika $7 D001943
650    _2
$a metylace DNA $7 D019175
650    _2
$a epigeneze genetická $7 D044127
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a hormony $7 D006728
650    _2
$a lidé $7 D006801
650    12
$a klíšťata $7 D013987
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Herzog, Chiara $u European Translational Oncology Prevention and Screening (EUTOPS) Institute, Milser Str. 10, 6060, Hall in Tirol, Austria $u Research Institute for Biomedical Aging Research, Universität Innsbruck, 6020, Innsbruck, Austria
700    1_
$a Kim, Yoo-Na $u European Translational Oncology Prevention and Screening (EUTOPS) Institute, Milser Str. 10, 6060, Hall in Tirol, Austria $u Research Institute for Biomedical Aging Research, Universität Innsbruck, 6020, Innsbruck, Austria
700    1_
$a Bartlett, Thomas E $u Department of Statistical Science, University College London, WC1E 7HB, London, UK
700    1_
$a Jones, Allison $u Department of Women's Cancer, UCL EGA Institute for Women's Health, University College London, Medical School Building, Room 340, 74 Huntley Street, WC1E 6AU, London, UK
700    1_
$a Evans, Iona $u Department of Women's Cancer, UCL EGA Institute for Women's Health, University College London, Medical School Building, Room 340, 74 Huntley Street, WC1E 6AU, London, UK
700    1_
$a Cibula, David $u Gynaecologic Oncology Center, Department of Obstetrics and Gynecology, First Faculty of Medicine, Charles University in Prague, General University Hospital in Prague, Prague, Czech Republic
700    1_
$a Zikan, Michal $u Department of Gynecology and Obstetrics, Charles University in Prague, First Faculty of Medicine and University Hospital Bulovka, Prague, Czech Republic
700    1_
$a Bjørge, Line $u Department of Obstetrics and Gynaecology, Haukeland University Hospital, Bergen, Norway $u Centre for Cancer Biomarkers CCBIO, Department of Clinical Science, University of Bergen, Bergen, Norway
700    1_
$a Harbeck, Nadia $u Breast Center, Department of Obstetrics and Gynecology, University of Munich (LMU), Munich, Germany
700    1_
$a Colombo, Nicoletta $u Istituto Europeo di Oncologia IRCCS, Milan, Italy $u University of Milano-Bicocca, Milan, Italy
700    1_
$a Howell, Sacha J $u Breast Biology Group, Manchester Breast Centre, Division of Cancer Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, UK
700    1_
$a Rådestad, Angelique Flöter $u Department of Women's and Children's Health, Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden
700    1_
$a Gemzell-Danielsson, Kristina $u Department of Women's and Children's Health, Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden
700    1_
$a Widschwendter, Martin $u European Translational Oncology Prevention and Screening (EUTOPS) Institute, Milser Str. 10, 6060, Hall in Tirol, Austria. martin.widschwendter@uibk.ac.at $u Research Institute for Biomedical Aging Research, Universität Innsbruck, 6020, Innsbruck, Austria. martin.widschwendter@uibk.ac.at $u Department of Women's Cancer, UCL EGA Institute for Women's Health, University College London, Medical School Building, Room 340, 74 Huntley Street, WC1E 6AU, London, UK. martin.widschwendter@uibk.ac.at $u Department of Women's and Children's Health, Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden. martin.widschwendter@uibk.ac.at $1 https://orcid.org/0000000277788380
773    0_
$w MED00006605 $t Genome biology $x 1474-760X $g Roč. 23, č. 1 (2022), s. 52
856    41
$u https://pubmed.ncbi.nlm.nih.gov/35189945 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20220720 $b ABA008
991    __
$a 20220804135604 $b ABA008
999    __
$a ok $b bmc $g 1822811 $s 1170612
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2022 $b 23 $c 1 $d 52 $e 20220222 $i 1474-760X $m Genome biology $n Genome Biol $x MED00006605
GRA    __
$p Department of Health $2 United Kingdom
LZP    __
$a Pubmed-20220720

Find record

Citation metrics

Archiving options